Regulatory approval

Published by the Health Service Executive.

The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab (subcutaneous - 21 days) in combination with either paclitaxel or docetaxel for reimbursement as a treatment option for the treatment of HER2 positive early breast cancer following adjuvant chemotherapy with doxorubicin and cyclophosphamide.

This is written in the approval document as:

HER2 positive early breast cancer (EBC) following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with PACLitaxel or DOCEtaxel.

Citation

Trastuzumab Subcutaneous 21 days - Early Breast Cancer, 2021, version number 4, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6700/285_v4_Trastuzumab_SC_21days_EBC.pdf

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
HSE (1) HER2-positive Invasive Breast Carcinoma Docetaxel, Trastuzumab
HSE (1) HER2-positive Invasive Breast Carcinoma Paclitaxel, Trastuzumab